Presidio pockets $26M in second VC round

San Francisco-based Presidio Pharmaceuticals, which is focused on developing therapies for chronic viral infections, has garnered $26 million in its second round. Panorama Capital led the round with Baker Brothers Investments, Bay City Capital, Ventures West Capital, Nexus Medical Partners and others participating.

"The proceeds of this financing will be used to advance two of our programs into human clinical studies, continue establishing alliances with outside partners, and expand our product portfolio through additional in-licensing transactions," said Dr. Omar K. Haffar, president and CEO of Presidio Pharmaceuticals.

- check out the release for more info

Related Article:
The top five VC deals of the first half of 2007. List

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.